Back to Journals » Clinical Epidemiology » Volume 3 » Supplement 1

Use of administrative hospital registry data and a civil registry to measure survival and other outcomes after cancer

Authors Toft Sorensen H, Lash T

Published 21 July 2011 Volume 2011:3(Supplement 1) Pages 1—2

DOI https://doi.org/10.2147/CLEP.S22509

Henrik Toft Sørensen, Timothy L Lash
Department of Clinical Epidemiology, Aarhus University Hospital, DK-8000 Aarhus, Denmark

For many decades, cancer registries have been a cornerstone in monitoring cancer occurrence in different populations. Cancer registries in the Nordic countries are characterized by a high level of completeness and excellent data quality.1 Cancer diagnoses are often validated through several procedures, with documentation of clinical evidence for the diagnosis. Cancer registries have proven very useful in monitoring cancer incidence, contributing significantly to our understanding of its origin and development. Some registries also have been used to monitor cancer survival at the population level.1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Multimorbidity and cancer outcomes: a need for more research

Sørensen HT

Clinical Epidemiology 2013, 5:1-2

Published Date: 1 November 2013

Setting the RECORD straight: developing a guideline for the REporting of studies Conducted using Observational Routinely collected Data

Langan SM, Benchimol EI, Guttmann A, Moher D, Petersen I, Smeeth L, Sørensen HT, Stanley F, Von Elm E

Clinical Epidemiology 2013, 5:29-31

Published Date: 7 February 2013

Erratum

Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:49-50

Published Date: 20 December 2012

The Danish national type 2 diabetes cohort – the DD2 study

Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:1-5

Published Date: 21 September 2012

Editor's choice

Sørensen HT

Clinical Epidemiology 2012, 4:157-158

Published Date: 9 July 2012

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

The potential clinical applications and prospects of microRNAs in lung cancer

Gao Y, Gao F, Ma JL, Sun WZ, Song LP

OncoTargets and Therapy 2014, 7:901-906

Published Date: 4 June 2014

Clinical epidemiology of epithelial ovarian cancer in the UK

Doufekas K, Olaitan A

International Journal of Women's Health 2014, 6:537-545

Published Date: 23 May 2014

How to reduce your cancer risk: mechanisms and myths

Nahleh Z, Bhatti NS, Mal M

International Journal of General Medicine 2011, 4:277-287

Published Date: 8 April 2011

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011

Biosensors: the new wave in cancer diagnosis

Brian Bohunicky, Shaker A Mousa

Nanotechnology, Science and Applications 2011, 4:1-10

Published Date: 30 December 2010